Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Ortho Clinical Diagnostics’ COVID-19 Antibody Test Gets FDA Emergency Use Approval

The FDA has granted Emergency Use Authorization (EUA) to Ortho Clinical Diagnostics’ (NASDAQ:OCDX) VITROS Anti-SARS-CoV-2 IgG Quantitative Test. The company says it…
byVandana Singh
July 12, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • The FDA has granted Emergency Use Authorization (EUA) to Ortho Clinical Diagnostics’ (NASDAQ:OCDX) VITROS Anti-SARS-CoV-2 IgG Quantitative Test.
  • The company says it the first quantitative COVID-19 IgG antibody test to receive a EUA nod.
  • Ortho’s new quantitative COVID-19 IgG antibody test targets the S1 spike protein and is intended for use in identifying individuals with an adaptive immune response to SARS-CoV-2. 
  • The test offers 100% specificity and excellent sensitivity, the company said in the press release.
  • The new test is calibrated to the World Health Organization International Standard for anti-SARS-CoV-2 IgG antibodies. 
  • Price Action: OCDX shares closed at $21.32 on Friday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts